New Perspective in Treatment of Community-Acquired Pneumonia

dc.contributor.advisorBrugós, László
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Tüdőgyógyászati Klinikahu_HU
dc.contributor.authorCheng, Yu-Fan
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentLieber, Attila
dc.contributor.opponentTimea, Durzak
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Tüdőgyógyászati Klinikahu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Infektológiai és Gyermekimmunológiai Tanszékhu_HU
dc.date.accessioned2022-08-18T08:42:38Z
dc.date.available2022-08-18T08:42:38Z
dc.date.created2022-06-09
dc.description.abstractPneumonia has been one of the top contenders for the leading cause of death for decades. Due to vague symptoms and unreliable laboratory examinations, treatment of community-acquired pneumonia relies on empiric use of antibiotics more than any other diseases. However, the high demand for antibiotics lead to the rise of multidrug-resistant pathogens; thus, increasing the difficulty of treatment of pneumonia. Future of treatment of community-acquired pneumonia will be dependent on two things. First, current restriction and regulation of antibiotics to slow down the development of microbial drug resistance. Second, encourage development of new medical and laboratory technologies and their applications. These new technologies can provide not only new methods of microbial termination, but also aid the diagnosis of pneumonia to gain earlier and with more precise drug treatment.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/336573
dc.language.isoenhu_HU
dc.subjectCommunity-Acquired Pneumoniahu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Tüdőgyógyászathu_HU
dc.titleNew Perspective in Treatment of Community-Acquired Pneumoniahu_HU
Fájlok